By the Peptide.Express Editorial Team
Research area
Quick Answer
Three compounds carry most of the tissue-repair literature in this catalogue, and they are not three versions of one mechanism. BPC-157 is a 15-residue peptide derived from human gastric juice (CAS 137525-51-0) that upregulates VEGF at the site it is applied to. TB-500 is synthetic Thymosin β-4; it sequesters monomeric G-actin and mobilises cells toward an injury from elsewhere in the body. GHK-Cu carries copper to the enzymes that crosslink collagen. Local angiogenesis, systemic cell recruitment, matrix chemistry — three separable levers, supplied at ≥99% HPLC purity for in-vitro laboratory research only.
Research context
BPC-157, TB-500 and GHK-Cu: which pathway in the repair cascade each one acts on, and where the evidence is strong or thin. Sourced to a ≥99% HPLC specification. Research use only.
Compare compounds
A repair site needs blood supply, arriving cells, and a matrix worth rebuilding into. Those are sequential requirements rather than competing ones, which is why comparative designs run these compounds in separate arms instead of treating them as interchangeable. One caveat belongs at the front: no receptor has ever been identified for BPC-157, despite well over a hundred preclinical studies, and almost all of that work is rodent. TB-500 is the exception in this group — Thymosin β-4 has been through human corneal and cardiac trials, which is more than most compounds in the repair category can say. GHK-Cu sits somewhere between the two, with a well-characterised cell-culture mechanism and a much weaker record in intact tissue.
Upregulates VEGF at the injury site and activates focal adhesion kinase and paxillin — the signalling proteins that decide whether a fibroblast can grip its substrate and move across it. Rat rotator cuff, Achilles and NSAID-induced gastric ulceration models are the standard preparations. The mechanism is a set of downstream observations, not a binding story.
Binds free G-actin through the LKKTET motif and shifts the G-to-F-actin equilibrium, which is what allows endothelial cells, keratinocytes and progenitor populations to migrate toward a wound from distant tissue. It acts systemically, not locally — the reason it is paired with BPC-157 in study designs rather than substituted for it.
Delivers Cu²⁺ to lysyl oxidase, the copper-dependent enzyme that crosslinks collagen and elastin fibrils, while raising collagen transcription and MMP-1 and MMP-2 activity at the same time. Synthesis without the matrix-clearing arm would give accumulation; the two running together is what produces turnover in culture.
BPC-157, TB-500 and GHK-Cu are the three with the largest repair literature. They act at different points: BPC-157 drives VEGF-mediated angiogenesis locally, TB-500 mobilises cells systemically through actin sequestration, and GHK-Cu supplies copper to matrix-crosslinking enzymes. A design that needs to attribute an effect to one of those steps needs separate arms.
They are frequently run together, and the rationale is mechanistic rather than additive: local repair activation paired with systemic cell recruitment covers two sequential requirements of the same cascade. What does not exist is combination pharmacokinetic data. Running each compound as an independent arm is the only way to attribute an outcome to migration versus angiogenesis.
For Thymosin β-4, yes — it has been investigated in human corneal and cardiac trials, which is unusual in this compound class. BPC-157 has no completed controlled human evaluation; its record is preclinical and overwhelmingly rodent. GHK-Cu human work is largely topical and dermatological. None of these compounds is approved for human use.
It is doing much of the work. GHK binds Cu²⁺ and acts as a courier, supplying bioavailable copper to lysyl oxidase, which crosslinks newly deposited collagen and elastin. Without that step new matrix has no tensile integrity. Research protocols treat GHK and GHK-Cu as different molecules for exactly this reason.
Repair-research compounds are sourced against a ≥99% HPLC specification. Mass and purity figures are the lines on the certificate for that lot, where a certificate is on file. For TB-500 specifically, check the CoA mass: the name is used inconsistently across suppliers for both full-length Thymosin β-4 and shorter LKKTET fragments.
Explore our complete catalog of research peptides. Same-day US shipping on orders before 2 PM EST. Sourced against a ≥99% HPLC purity specification. Third-party Certificates of Analysis are published where on file. For laboratory research use only. Not for human or veterinary use.
Compiled by the Peptide.Express Editorial Team. Written and reviewed by Peptide.Express Editorial Team. Molecular identity on this page (name, CAS number, molecular formula and molecular weight) is resolved from a single internal entity record and checked against primary registries (PubChem, CAS Common Chemistry) rather than retyped per page. A field with no verified value is left out instead of estimated. Literature is cited to a DOI, PMID or PMCID permalink so every reference resolves to the specific record it names.